drugset / Trial / NCT00044148
The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes
Treatment
Summary
The purpose of this study are to determine 1) Whether Ly333531 can reduce urinary albumin/creatinine excretion in patients with Type II diabetes and persistent albuminuria 2) Whether LY333531 reduces urinary TGF-B, 3) the safety of LY333531 and any side effects that may be associated with it.
Timeline
- Start
- 2002-07-16
- Primary completion
- 2004-04-28
- Completion
- 2004-04-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ruboxistaurin | Small molecule | — | — |